<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03090386</url>
  </required_header>
  <id_info>
    <org_study_id>16-005834</org_study_id>
    <nct_id>NCT03090386</nct_id>
  </id_info>
  <brief_title>Evaluation of Cognitive-Communication Deficits Following Treatment of Primary Brain Tumor Patients</brief_title>
  <official_title>Evaluation of Cognitive-Communication Deficits Following Treatment of Primary Brain Tumor Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate which cognitive-linguistic symptoms are most commonly experienced
      following brain tumor treatment. Cognitive surveys will be administered after treatment of
      primary brain tumor cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2017</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive Communication Survey</measure>
    <time_frame>1 day at time of consent</time_frame>
    <description>Survey is completed at time of consent</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive-linguistic Standardized Testing</measure>
    <time_frame>within 3 months of cognitive communication survey</time_frame>
    <description>Standardized testing will be completed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow-up Survey</measure>
    <time_frame>within 6 months after completion of standardized testing</time_frame>
    <description>Survey will be completed</description>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Brain Tumor</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cognitive Surveys</intervention_name>
    <description>Complete the Cognitive Communication Survey, standardized cognitive and language assessments, and the Follow-up Cognitive Communication Survey after treatment</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        adults diagnosed with a malignant brain tumor either as a primary diagnosis or recurrent
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  be between18 to 89 years old;

          -  have undergone at least one cycle of a cancer treatment regimen (e.g., chemotherapy,
             radiotherapy, surgery)

          -  have completed at least one cycle of a cancer treatment regimen within five years of
             enrollment in the study;

          -  be native speakers of American English;

          -  have obtained a minimum of a high school education;

          -  self-report at least one cognitive-linguistic or social-emotional deficit as assessed
             by the FACT-BR; and

          -  must demonstrate capacity to sign informed consent based on Informed Consent for
             Research: A Guide to Assessing a Participant's Understanding tool.

        Exclusion Criteria:

          -  are younger than 18 years old or older than 89 years old;

          -  have not undergone at least one cycle of a cancer treatment regimen following
             diagnosis (e.g., chemotherapy, radiotherapy, surgery)

          -  have not undergone at least one cycle of a cancer treatment regimen in the five year
             period prior to enrollment;

          -  are not native speakers of American English;

          -  have not obtained a minimum of a high school education;

          -  do not self-report at least one cognitive-linguistic or social-emotional deficit as
             assessed by the FACT-BR; or

          -  do not demonstrate the capacity to sign informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2017</study_first_submitted>
  <study_first_submitted_qc>March 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2017</study_first_posted>
  <last_update_submitted>February 7, 2018</last_update_submitted>
  <last_update_submitted_qc>February 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Nadia N. Laack, M.D.</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

